Section of Nephrology
and Hypertension

1542 Tulane Avenue
Room 330, Box T4M-2
New Orleans, LA  70112


Katy Smith

Fellowship Coordinator

Phone:  504-568-8655
Fax:      504-568-2127







Section of Nephrology and Hypertension

ReisinWelcome to the Section of Nephrology and Hypertension in the Department of Medicine at the School of Medicine of the Louisiana State University Health Sciences Center in New Orleans. We are dedicated to providing the highest level of medical care to patients, advancing the science and art of nephrology through research and discovery, and training physicians and investigators to become leaders in the medicine and science of nephrology.

The Section of Nephrology and Hypertension sees patients with a wide range of conditions, including diabetes, hypertension, and all stages of chronic kidney disease, as well as patients in hemodialysis and peritoneal dialysis.  The section has its own interventional nephrology unit as well as faculty who are dedicated to clinical practice, research, and teaching.

Our goal is to provide the highest-quality care while helping patients manage their conditions.  Though the section provides expertise in all areas of nephrology, we also have faculty with additional expertise in specific areas; these faculty members provide care through specialty clinics and teach medical students, medical residents, nephrology fellows, and other doctors in the community. The Section of Nephrology and Hypertension has a close association with the School of Medicine’s clinical and basic-science departments and provides medical care through our clinics to approximately 5,000 patients annually.

The Nephrology fellowship program emphasizes clinical training in the diagnosis and treatment of renal diseases and hypertension, as well as a basic understanding of renal physiology and pathophysiology.

The Section of Nephrology and Hypertension has an active research program and is committed both to investigating the underlying causes of kidney disease and to finding new ways to treat it.




Aguilar, Erwin, PharmD, MS, MPH
Morse, Stephen M., DO, MPH
Naljayan, Mihran V., MD
Reisin, Efrain, MD, FACP, FAP
Vareldzis, Ramzi, MD
Yazdi, Farshid, MD, MSPH


Office Staff:

Fellowship Program 

Naljayan, Mihran V., MD - Program Director

The Section of Nephrology offers a fellowship program with transplant experiences at the Ochsner Foundation Hospital. The program is accredited and approved for a total of five fellows at this time.


The Section of Nephrology and Hypertension’s Office of Research participates in various investigator-initiated and industry-sponsored clinical trials involving both current standards of care as well as new and novel therapies. The section has actively participated in Phases I-IV of FDA-regulated trials in the areas of hypertension, diabetic nephropathy, dialysis access, bone mineral metabolism, and anemia in patients with chronic kidney disease as well as patients on hemodialysis and peritoneal dialysis. 

In addition to regular medical care, the section offers patients access to novel treatments that are unavailable except in clinical trials.  Additionally, nephrology fellows, medical students, and internal medicine residents are given the opportunity to participate actively as investigators in relevant current clinical trials and to provide input on designing, implementing, and publishing the results of investigator-initiated studies.

Currently, active trials are ongoing in the areas of diabetic nephropathy and anemia with investigator-initiated trials in the areas of job-stress-related hypertension and hypertension management in geriatric populations.

For more information, call 504-568-2553

Efrain Reisin, MD, FACP, FAP - Section Chief

Erwin Aguilar, PharmD, MS, MPH - Associate Professor of Research

Sean Barry, BSc - Clinical Research Associate

Students and residents can participate in various clinical or animal research projects. The focus of research are in the areas of obesity hypertension, job stress related hypertension, the effects of new antihypertensive drugs, as well as new medications for End Stage Renal Disease, with a particular interest in the assessment of the effects of various treatments in the progression of renal disease, or in the prevention of complications in the dialysis patient.